Boris Gershman

2.5k total citations
99 papers, 1.6k citations indexed

About

Boris Gershman is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Boris Gershman has authored 99 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 47 papers in Surgery and 17 papers in Molecular Biology. Recurrent topics in Boris Gershman's work include Bladder and Urothelial Cancer Treatments (38 papers), Renal cell carcinoma treatment (30 papers) and Prostate Cancer Diagnosis and Treatment (30 papers). Boris Gershman is often cited by papers focused on Bladder and Urothelial Cancer Treatments (38 papers), Renal cell carcinoma treatment (30 papers) and Prostate Cancer Diagnosis and Treatment (30 papers). Boris Gershman collaborates with scholars based in United States, Canada and Italy. Boris Gershman's co-authors include Stephen A. Boorjian, R. Houston Thompson, Bradley C. Leibovich, Daniel M. Moreira, Brian A. Costello, John C. Cheville, Christine M. Lohse, Simon P. Kim, Dragan Golijanin and R. Jeffrey Karnes and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and The Journal of Urology.

In The Last Decade

Boris Gershman

92 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Boris Gershman United States 25 1.1k 666 475 191 176 99 1.6k
Christian D. Fankhauser Switzerland 22 697 0.7× 812 1.2× 452 1.0× 280 1.5× 309 1.8× 141 2.0k
Stephen E. Strup United States 24 1.2k 1.2× 536 0.8× 550 1.2× 175 0.9× 229 1.3× 92 1.9k
Jean‐Baptiste Lattouf Canada 24 670 0.6× 718 1.1× 376 0.8× 267 1.4× 102 0.6× 93 1.5k
Roy Mano Israel 20 829 0.8× 562 0.8× 428 0.9× 297 1.6× 92 0.5× 106 1.4k
Angelo Porreca Italy 22 970 0.9× 494 0.7× 219 0.5× 167 0.9× 271 1.5× 131 1.6k
Steffen Rausch Germany 21 564 0.5× 476 0.7× 497 1.0× 292 1.5× 72 0.4× 122 1.4k
Guilherme Godoy United States 29 1.5k 1.4× 1.4k 2.1× 551 1.2× 285 1.5× 365 2.1× 86 2.7k
J. Rubio‐Briones Spain 20 879 0.8× 497 0.7× 436 0.9× 171 0.9× 346 2.0× 135 1.7k
Sven Wenske United States 21 684 0.6× 283 0.4× 188 0.4× 172 0.9× 185 1.1× 41 1.2k
E. Becht Germany 23 825 0.8× 441 0.7× 413 0.9× 149 0.8× 202 1.1× 58 1.4k

Countries citing papers authored by Boris Gershman

Since Specialization
Citations

This map shows the geographic impact of Boris Gershman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Gershman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Gershman more than expected).

Fields of papers citing papers by Boris Gershman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Gershman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Gershman. The network helps show where Boris Gershman may publish in the future.

Co-authorship network of co-authors of Boris Gershman

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Gershman. A scholar is included among the top collaborators of Boris Gershman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Gershman. Boris Gershman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Robin, Tyler P., et al.. (2024). Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. Urologic Oncology Seminars and Original Investigations. 42(12). 447.e17–447.e24. 3 indexed citations
2.
3.
Fleishman, Aaron, Ruslan Korets, Peter Chang, et al.. (2023). Conditional survival following radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology Seminars and Original Investigations. 41(10). 432.e11–432.e20.
4.
Lu, Yujia, et al.. (2023). The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States. Urologic Oncology Seminars and Original Investigations. 41(9). 389.e1–389.e6. 2 indexed citations
5.
Pessoa, Rodrigo Rodrigues, Badrinath R. Konety, Boris Gershman, et al.. (2021). National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urologic Oncology Seminars and Original Investigations. 39(12). 832.e9–832.e15. 1 indexed citations
6.
Brito, Joseph, Anna Moshnikova, Boris Gershman, et al.. (2019). Ex-vivo Imaging of Upper Tract Urothelial Carcinoma Using Novel pH Low Insertion Peptide (Variant 3), a Molecular Imaging Probe. Urology. 139. 134–140. 15 indexed citations
7.
Brito, Joseph, Jorge Pereira, Daniel M. Moreira, et al.. (2018). The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP). Prostate Cancer and Prostatic Diseases. 21(2). 245–251. 6 indexed citations
8.
Lyon, Timothy D., Boris Gershman, Paras Shah, et al.. (2018). Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. Urologic Oncology Seminars and Original Investigations. 36(11). 499.e1–499.e7. 5 indexed citations
9.
Gershman, Boris, R. Houston Thompson, Stephen A. Boorjian, et al.. (2018). Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. European Urology. 74(6). 825–832. 51 indexed citations
10.
Gershman, Boris, Daniel M. Moreira, R. Houston Thompson, et al.. (2017). Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. European Urology. 72(2). 300–306. 55 indexed citations
11.
Gershman, Boris, Daniel M. Moreira, R. Houston Thompson, et al.. (2017). Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score–based Analysis. European Urology. 73(3). 469–475. 10 indexed citations
12.
Moreira, Daniel M., et al.. (2015). Association of estimated glomerular filtration rate with 24-h urinalysis and stone composition. Urolithiasis. 44(4). 319–325. 4 indexed citations
13.
Gershman, Boris, Stephen A. Boorjian, & Richard E. Hautmann. (2015). Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?. Bladder Cancer. 2(1). 1–14. 6 indexed citations
14.
Westerman, Mary E., Boris Gershman, R. Jeffrey Karnes, et al.. (2015). Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy. World Journal of Urology. 34(8). 1115–1122. 11 indexed citations
15.
Barrisford, Glen W., Boris Gershman, & Michael L. Blute. (2014). The role of lymphadenectomy in the management of renal cell carcinoma. World Journal of Urology. 32(3). 643–649. 7 indexed citations
16.
Gershman, Boris, et al.. (2012). Relationship Between Glomerular Filtration Rate and 24-Hour Urine Composition in Patients With Nephrolithiasis. Urology. 80(1). 38–42. 17 indexed citations
17.
Gershman, Boris, Anthony L. Zietman, Adam S. Feldman, & W. Scott McDougal. (2012). Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. Urologic Oncology Seminars and Original Investigations. 31(7). 1093–1097. 34 indexed citations
18.
Gershman, Boris, Naveen M. Kulkarni, Dushyant V. Sahani, & Brian H. Eisner. (2011). Causes of renal forniceal rupture. British Journal of Urology. 108(11). 1909–1911. 63 indexed citations
19.
Gershman, Boris, Douglas M. Dahl, Aria F. Olumi, et al.. (2011). Smaller prostate gland size and older age predict Gleason score upgrading. Urologic Oncology Seminars and Original Investigations. 31(7). 1033–1037. 40 indexed citations
20.
Kutikov, Alexander, Keith VanArsdalen, Boris Gershman, et al.. (2008). Enucleation of renal cell carcinoma with ablation of the tumour base. British Journal of Urology. 102(6). 688–691. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian D. Fankhauser Breakdown of academic impact, for papers by Stephen E. Strup Breakdown of academic impact, for papers by Jean‐Baptiste Lattouf Breakdown of academic impact, for papers by Roy Mano Breakdown of academic impact, for papers by Angelo Porreca Breakdown of academic impact, for papers by Steffen Rausch Breakdown of academic impact, for papers by Guilherme Godoy Breakdown of academic impact, for papers by J. Rubio‐Briones Breakdown of academic impact, for papers by Sven Wenske Breakdown of academic impact, for papers by E. Becht
Rankless by CCL
2026